Rayonier vs Sabra Health Care REIT
RYN and SBRA side by side, both in miscellaneous investing. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How RYN and SBRA compare
Rayonier is the larger company, worth 1.2 times as much as Sabra Health Care REIT ($6.4B against $5.2B).
On earnings, Rayonier is cheaper: it trades at 47.8× trailing earnings, against 73.0× for Sabra Health Care REIT.
Sabra Health Care REIT grew revenue faster over the last twelve months (23.4% versus 0.44% for Rayonier).
Rayonier keeps more of each dollar of sales as profit, with a net margin of 7.8% compared with 7.8% at Sabra Health Care REIT.
Both pay dividends: Rayonier yields 4.9% and Sabra Health Care REIT 7.3%.
Rayonier scores higher on the StockData Score (8 against 6 for Sabra Health Care REIT), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | RYN | SBRA |
|---|---|---|
| Size and price | ||
| Market cap | $6.4B | $5.2B |
| Share price | $21.50 | $20.44 |
| Change, 1 year | −2.9% | 8.3% |
| Change, 5 years | −46.2% | 43.7% |
| Beta (5Y) | 0.69 | 0.46 |
| Employees | 285 | 58 |
| StockData Score | ||
| Total score | 8 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 | 2 (better) |
| Health score | 3 (better) | 0 |
| Dividend score | 3 | 3 |
| Valuation | ||
| P/E | 47.8× (better) | 73.0× |
| P/S | 6.6× | 5.7× (better) |
| P/B | 1.2× (better) | 1.8× |
| EV/EBITDA | 136× | 12.7× (better) |
| PEG | 0.79 | – |
| Fair value | $14.81 | $12.97 |
| Margin of safety | −45.1% (better) | −57.6% |
| Growth | ||
| Revenue growth (TTM) | 0.44% | 23.4% (better) |
| Revenue growth, 5Y average | −10.8% | 5.3% (better) |
| Net income growth (TTM) | −90.0% | −59.2% (better) |
| EPS growth (TTM) | −90.9% | −61.1% (better) |
| EPS growth, 5Y average | 62.2% (better) | −0.91% |
| Profitability | ||
| Gross margin | 23.7% | – |
| Operating margin | 6.0% | – |
| Net margin | 7.8% (better) | 7.8% |
| Return on equity | 2.0% | 2.5% (better) |
| Return on invested capital | 1.3% | – |
| Financial health | ||
| Debt / equity | 0.36 | – |
| Net debt / EBITDA | 25.02 | – |
| Interest coverage | 1.3× | – |
| Current ratio | 3.56 | – |
| Altman Z-score | 1.94 (better) | 1.38 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 4.9% | 7.3% (better) |
| Payout ratio | 393% | 423% |
| Years of dividend growth | 0 | 0 |
| Dividend growth, 5Y average | 18.2% (better) | −2.3% |
| Buyback yield | 0.05% | – |
| Shareholder yield | 5.0% | 7.3% (better) |
| Ownership | ||
| Held by institutions | 94.2% | 102% |
| Held by insiders | 1.0% | 1.9% |
| Insider net buying, 12 months | −$3.8M (better) | −$4.7M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 4.9% | 7.1% |
Go deeper
- RYN stock overview
- RYN income statement
- RYN valuation and score
- SBRA stock overview
- SBRA income statement
- SBRA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.